Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anchor secures $480 million GPCR deal

This article was originally published in Scrip

Executive Summary

Ortho-McNeil-Janssen Pharmaceuticals, the Johnson & Johnson company, has signed a collaboration and licence agreement with Anchor Therapeutics to enhance its ability todevelop G protein coupled receptor (GPCR)-targeted therapeutic compounds. The deal gives J&J access to Anchor's pepducin technology which it says represents a new approach to modulating GPCR signal transduction. GPCRs, the largest class of pharmaceutical targets, are notoriously intractable owing to their instability when taken out of their transmembrane localities.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC010133

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel